Specialty Programs

Specialty Programs — Complex Modalities, Hard Problems, Clean Execution

Dual hubs: San Diego, CA (Southern California) & Montréal, Canada
Scope: Bispecifics and multi-specifics, Fc engineering and glyco-tuning, site-specific conjugation and conjugated biologics (e.g., ADC-like concepts under appropriate containment), high-concentration SC formulations, membrane/secretory “difficult proteins,” enzyme replacement (ERT) and glycoproteins, cell-free expression (select programs), continuous bioprocess options (USP/DSP), isotopic/enriched research-grade reagents (select), and “legacy to modern” process remastering—delivered end-to-end within a unified digital QMS (ALCOA+).

Complex programs stall for familiar reasons: quality attributes fight each other, upstream settings don’t translate to purification, filtration collapses high-viscosity drug product, or the file can’t defend sameness after a change. Specialty work is where those contradictions get resolved. We take the same approach we use everywhere—define what must be true at the dose and on the dossier, then write the ranges that actually hold—but we add deeper mechanism-aware development, more orthogonal analytics, and stricter operator-holdable boundaries. The aim is not novelty for its own sake; it’s a process you can run, inspect, and scale without improvisation.

Why teams route specialty work to MycoVista

Context. Specialty projects live at the edge of platform comfort—bispecific assembly, ADC-like conjugation, PEGylation or long-acting formats, membrane proteins that punish shear, or ERTs whose glycan profile drives function. The way through is a program that converts constraints into designs, and designs into batch records that read cleanly. We do that with:

  • End-to-end ownership. Design → CLD/strain → USP (fed-batch, perfusion, intensified microbial) → DSP (capture/polish/viral safety/UF-DF) → analytics → formulation/DP (liquid, lyo, or high-concentration SC) → stability → submission—mirrored methods and documents across San Diego & Montréal.
  • Mechanism-aware development. We align CQAs with mechanism (e.g., Fc effector function, bispecific mis-pairing, linker stability, glycan windows for ERTs) and design CPPs that directly control them.
  • Orthogonality by default. We plan complementary assays where they actually lower risk (e.g., glycan + charge, SEC-MALS + CE-SDS, empty/full + orthogonal confirmation, potency paired with mechanism-specific surrogates).
  • Containment and practicality. For conjugation or HPAPI-adjacent steps, we operate within defined OELs using closed processing and validated cleaning; above our in-house envelope, we use qualified partners with the same documentary standards.
  • Evidence over optimism. If a setting cannot be held by trained operators on a night shift, it is not “locked.” If an attribute lacks an assay with acceptance criteria, it is not “controlled.” We make both true before PPQ.

Background: the constraints that actually govern specialty success

Specialty biologics fail late for a handful of recurring causes:

  1. Attribute friction. A feed or residence-time change that raises titer but breaks a charge/glycan window or pushes aggregates.
  2. Assembly fidelity gaps. Bispecific pairing, chain imbalance, or proteolytic clip discovered after “platform” conditions are assumed.
  3. Purification realism. Capture loads sized on buffer trials rather than harvests; polishing recipes that collapse at production linear velocities.
  4. Drug-product physics. High-concentration SC viscosity, shear sensitivity in sterile filtration, or a lyo cycle tuned to appearance rather than residual moisture and reconstitution time.
  5. Documentation drift. Method transfers that change answers; change control without prespecified comparability; batch records that don’t match the control strategy.

We address all five on day one: write the control strategy, test on real intermediates, prove orthogonality where it reduces risk, and translate design space into recipes with interlocks and alarms.

Program spine: QTPP → CQAs → CPPs (written first, then executed)

QTPP (intended product and use): route (IV/SC/IT/intranasal as applicable), dose and presentation (vial/PFS; liquid/lyo; concentration target), key functional readouts (potency mechanism, effector function, payload ratio if conjugated), stability and shipping truth, acceptable residuals and leachables, and device constraints for SC programs.

CQAs (measured attributes):

  • Structure/identity: intact mass/peptide map; subunit confirmation; correct pairing for multi-specifics.
  • Purity/variants: SEC-MALS (aggregates), icIEF/IEF (charge), CE-SDS (R/NR), glycans (released/site-specific when needed).
  • Function: potency aligned to MoA; Fc effector (ADCC/CDC) or receptor binding for Fc-tuned formats; enzymatic activity for ERTs.
  • Conjugation (where applicable): DAR or payload distribution, linker stability surrogates, residual free payload/linker.
  • Safety/residuals: HCP/DNA, Protein A, endotoxin/bioburden/sterility, detergents/solvents where applicable.
  • DP-specific: viscosity, filter recovery, residual moisture (lyo), reconstitution time, headspace oxygen (if oxidation-sensitive).

CPPs (controlled levers): promoter/UTR/signal peptide; selection pressure; feed/temperature/osmolality; perfusion residence time; shear/impeller and sparger regime; capture loading/residence; polishing gradients/ionic strength; viral inactivation pH/time; UF/DF TMP/cross-flow; conjugation stoichiometry/pH/solvent and quench; DP buffer, excipients, filtration ΔP/T, lyo shelf temps/pressures.

Specialty streams

1) Bispecifics & multi-specifics

Longer intro. Multi-specific formats replace simplicity with control surfaces: chain selection, pairing fidelity, post-translational discipline, and purification that separates look-alikes. We design for assembly fidelity first, then for yield.

  • Design: knob-in/knob-out, common light chain, CrossMab-like geometries, or fragment-based constructs—chosen for manufacturability given your biology.
  • CLD: pool screens run under process-relevant feeds/temperature, not growth media alone; clonality dossiers and stability under intended conditions.
  • DSP: capture that tolerates imbalance; polishing that resolves mis-paired species (IEX/HIC/MM tuned to your impurity map).
  • Analytics: subunit LC-MS, non-reduced CE-SDS, targeted peptide maps for chain identity, functional binning by epitope or receptor.

2) Conjugated biologics (site-specific and classical)

Longer intro. Conjugation is chemistry plus containment. We keep it sober: define target distribution, validate quench and cleanup, and keep operator exposure in limits.

  • Routes: enzymatic handles, engineered cysteines, click-like chemistries, or controlled lysines—selected for uniformity and cleanup feasibility.
  • Containment: closed processing; validated cleaning with defensible MACO/PDE; PPE and OEL controls; beyond our in-house envelope, we execute through qualified partners under our documentation model.
  • Analytics: DAR or analogous payload distribution; residual free payload/linker; potency before/after conjugation; stability studies tuned to linker chemistry.

Note: We do not publish payload brands; we scope each program’s OEL and validation footprint explicitly before commitment.

3) Fc engineering & glyco-tuning

Longer intro. Effector function depends on Fc design and glycan distribution. We treat both as process outputs, not afterthoughts.

  • Design & CLD: Fc variants chosen with comparability in mind; feed/temperature regimes that steer glycan windows; perfusion where residence time matters.
  • Analytics: Fc receptor binding panels, ADCC/CDC as MoA requires; glycan profiling (released and, when justified, site-specific).
  • DSP: polishing that protects charged/glycan variants; UF/DF and hold times validated against oxidation/deamidation risk.

4) Difficult proteins (membrane/secreted, clip-prone, redox-sensitive)

Longer intro. These are the “why won’t it express” or “why did it fall apart” cases. We assume they’re right—and we build around them.

  • Expression: periplasmic or secretion routes (CHO/HEK, yeast/fungi) to reduce endotoxin/protease burden; refold routes only when activity supports the economics.
  • Process physics: shear and oxygen transfer tuned to sensitivity; antifoam logic that doesn’t punish filters; cold operations where clip risk dominates.
  • Analytics: instability watchlists (clip, oxidation, deamidation) from development through DP.

5) Enzyme Replacement Therapy (ERT) & glycoproteins

Longer intro. Activity depends on glycan structure and folding; uptake often depends on a specific tag. We design to those truths.

  • CLD/USP: feed and residence-time strategies that steer glycan windows; stability gating under process conditions.
  • DSP: polishing to remove clipped/over-processed species; UF/DF that preserves activity.
  • DP: buffers that protect function; lyo cycles tuned to residual moisture and reconstitution without activity loss.

6) Cell-free protein expression (select programs)

Longer intro. For certain discovery or hard-to-express targets, cell-free systems offer speed and unique chemistries. We run them where they help—and only where they help.

  • Scope: lysate preparation, reaction optimization, and downstream cleanup tuned to the product’s analytical truth.
  • Positioning: research to early clinical feasibility; we define limits up front.

7) Continuous and intensified bioprocess

Longer intro. Continuous is a tool, not a doctrine. We adopt it when validation is clean and operations can actually run it.

  • USP: N-1 perfusion and true perfusion where cycle time and quality justify; residence-time control proven.
  • DSP: multi-column capture or membrane flow-through where lifecycle wins; in-line conditioning to reduce tank complexity.
  • Validation: batch definition, RTD characterization, PAT hooks; change control and comparability specified.

8) High-concentration SC and non-standard routes

Longer intro. Concentration converts formulation into mechanics. We design for syringeability and filterability, then check comfort and device.

  • DP: viscosity control (temperature, excipients), filter recovery under ΔP/T windows, device compatibility (glide force, needle gauge), and headspace oxygen where oxidation matters.
  • Lyo: cycles designed from collapse/eutectic mapping; reconstitution targets enforced.

9) Isotopic/enriched research-grade reagents (select)

Longer intro. For structural biology or analytics, we support ^13C/^15N/^2H enrichment at research scale with documented traceability—positioned outside GMP unless explicitly scoped.

Analytics & characterization (orthogonal panels that reduce risk)

Identity/purity: LC-MS (intact/subunit), peptide mapping, CE-SDS (R/NR), SEC-MALS, icIEF/IEF, glycan profiling (released ± site-specific).
Function: potency aligned to MoA; Fc receptor panels; activity for enzymes.
Conjugation-specific: DAR/payload distribution; residual free payload/linker; linker stability surrogates.
Residuals & safety: HCP/DNA, Protein A, endotoxin/bioburden/sterility; detergents/solvents where relevant.
DP: viscosity, filtration recovery, residual moisture (lyo), reconstitution time, headspace oxygen; extractables/leachables where risk warrants.
Lifecycle: development → transfer (dual hubs) → qualification/validation; OOS/OOT governance; change control and comparability when anything material changes.

Downstream with real harvests (capture → polish → viral safety → UF/DF)

We size columns, gradients, membranes, and filter trains on real intermediates at realistic linear velocities and fluxes; we don’t lock “buffer wins.” We plan caustic cleaning where resins tolerate it and document lifecycle limits (cycles, performance drift, bioburden risk). Viral inactivation/filtration is engineered with pressure–time models to avoid catastrophic flux loss. UF/DF staging avoids shear and osmotic shocks; aggregation thresholds are discovered during development, not at release.

Formulation & Drug Product (liquid, high-concentration, lyo)

Buffers and excipients are selected to protect potency and stability first; marketing adjectives come last. We prove sterile filtration feasibility early; where it harms function, we switch to validated aseptic operations in isolators or RABS with media fills that reflect real interventions. For lyo, cycles come from physics—collapse/eutectic points, annealing logic, primary/secondary drying—then we set residual moisture and reconstitution targets and hold them. We validate holds and shipping lanes that reflect how sites actually work.

Facilities & scale (what’s real and available)

  • USP: mammalian single-use 50 L and 250 L GMP suites, plus benchtop and multi-thousand-liter perfusion footprints; microbial/fungal bench → pilot → to 50,000 L stainless (qualified programs).
  • DSP: pilot to GMP chromatography/TFF skids; viral filtration capability; recipe control with qualified sensors; multi-column options where warranted.
  • DP: vial and PFS in isolators/RABS; CCIT platforms; automated/manual inspection; lyophilizers with shelf mapping.
  • Suites & utilities: ISO 8/7, positive pressure cascades, HEPA, unidirectional flows; BSL-2 where required; validated HPW/clean steam/compressed air with continuous trending.
  • Digital backbone: validated CDS/LIMS/ELN and eBMR/eBR; audit trails, access control, versioned methods—one spine across both hubs.

Regulatory & QMS posture (how the file reads and survives)

  • QbD for real. We map QTPP → CQAs → CPPs in protocols and transcribe ranges into batch records with interlocks.
  • Digital QMS (ALCOA+). Deviation/CAPA, change control, method lifecycle, training, and investigations—mirrored across hubs.
  • Authoring. CMC sections reflect actual methods and data; reviewer Q&A answered with tables and statistics plans.
  • Comparability. Prespecified for site/scale/material/conjugation changes; acceptance windows and orthogonal confirmations where they lower reviewer doubt.
  • Containment & cleaning. OELs documented; cleaning validation with MACO/PDE math and periodic verification; E/L where risk warrants.

Program Onboarding (your first 30 days)

  1. Control strategy draft—QTPP → CQAs (structure, function, variants, residuals, DP physics) → CPPs (CLD/USP/DSP/conjugation/DP) with proposed acceptance criteria.
  2. DoE plan—targeted to the two or three levers that actually govern your risk (e.g., pairing fidelity, linker stability, glycan window, viscosity/filtration for SC). Includes sampling plans and pass/fail criteria.
  3. Gantt & risk register—Stabilize → Optimize → Lock gates; preliminary specification proposal; stability design; and if applicable, containment and cleaning validation scope.

Send current data (construct, titers, quality pain points, DP feasibility notes). We respond with a written plan, dates, and pass criteria.

Indicative timelines (biology- and physics-gated)

  • Feasibility (2–6 weeks): construct/host confirmation; early expression; capture/polish shortlist; conjugation or glycan feasibility hypothesis; DP screen (filtration/viscosity/lyo).
  • Development (2–4 months): focused DoE on assembly or conjugation, feed/residence-time tuning, capture/polish limits, UF/DF and DP recipes, analytics qualification, stability bins.
  • Engineering runs: scale-similar hydrodynamics; mass balance and trending; filtration feasibility; comparability designs for any intended change.
  • Lock: process description, CPP ranges, validation plans (cleaning/hold time/viral clearance or process simulations), specification proposals, submission text.

We state gates and pass criteria; biology and physics set the pace.

Tech transfer & rescue (when specialty programs arrive mid-story)

We stabilize first, then optimize.

  • Triage: batch/deviation history; method files; stability; change controls; conjugation containment/cleaning; resin/membrane lifecycles; DP failures (viscosity, filter collapse, lyo issues).
  • Gap map: which CQAs are unguarded; which CPPs drift; what fixes buy the most risk reduction first (pairing fidelity, glycan control, linker stability, DP physics).
  • Stabilize → optimize → re-lock: interim setpoints to stop failures; targeted DoE on real drivers; comparability for any change; lifecycle files updated.

Deliverables (what you receive)

  • Control strategy and process description (design space, CPPs).
  • CLD/strain dossier (clonality/stability) or conjugation plan (stoichiometry, cleanup, containment).
  • DSP package (capture/polish, viral safety, UF/DF; lifecycle for resins/membranes).
  • Analytics (methods; transfer; qualification/validation; trending; function panels; DAR/payload where applicable).
  • DP files (filtration feasibility, viscosity/SC device compatibility; lyo cycle with residual moisture and reconstitution metrics).
  • Stability protocols/data with shelf-life rationale.
  • Validation & cleaning dossiers (hold time, media fills/process simulations if aseptic; cleaning validation with MACO/PDE).
  • Batch records (eBMR/eBR) and CMC text ready for submission.

Frequently asked (concise answers)

Do you run true ADCs? We support conjugated biologics under defined OELs with closed processing and validated cleaning; beyond that envelope, we execute via qualified partners under our documentation model.
Can you lock a glycan window? We design feed/residence time and validate with released ± site-specific glycans; we set acceptance windows and monitor drift by icIEF and glycan profiling.
High-concentration SC? We control viscosity, verify sterile-filter recovery, and confirm device compatibility (glide force/needle). If lyo wins, we design the cycle from physics and hold residual moisture/reconstitution times.
Continuous bioprocess? Only where validation is clean and operations can hold it. Batch definition, RTD, and PAT are part of the file.
Will you take over a failing specialty program? Yes—if the risk register says we can keep patients safe and data clean. We stabilize, then optimize, then re-lock.

Summary

Specialty work is not a promise of cleverness; it is a promise of control. We write down what “good” means, we design the process that produces it, and we prove sameness when we change. If you want a concrete plan—constraints, experiments, ranges, and documents—send your current data and we’ll return a design space and a path to GMP that survives both production and inspection.

MycoVista | San Diego, CA & Montréal, Canada
Start Program Onboarding → Share construct or product class, quality/potency goals, and DP constraints. We’ll return a control strategy, focused DoE, and a documented path to GMP.

EN / FR support available.